Samsung Biologics and ImmuneOncia Therapeutics held a signing ceremony for a contract to develop and manufacture five candidate molecules, expanding upon the two companies’ existing CDO partnership first established in 2018.   “As we already have a track record of successful collaboration between the two companies, I look forward to seeing what this strategic partnership can achieve in delivering our new products to market faster,” said Yun Jeong Song, chief executive officer, ...